• Bladder Cancer Indication Withdrawn for Durvalumab

    12 days ago - By Medscape

    AstraZeneca is withdrawing durvalumab's indication for the treatment of metastatic bladder cancer after a phase 3 trial showed no survival benefit.
    Medscape Medical News
    Read more ...